If you have been reading about synaptic plasticity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-26. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
== Pharmacokinetics == A cross-over study in six healthy volunteers (median age 28 years) was conducted using single-dose pharmacokinetics of 5 mg clotiazepam drops, oral tablets, and sublingual tablets. The formulations had similar systemic availability. Compared with oral tablets, the sublingual route gave a lower peak concentration and a delayed peak time, while drops gave a greater maximum concentration with a similar peak time. The use of drops is suggested for a more marked initial effect and the sublingual route for easier administration, especially in the elderly.
Hydrogen bonds: six main chain hydrogen bonds and three side chain hydrogen bonds can be made Van Der Waals interactions: Phe 49 and Leu 57 can form Van Der Waals interactions across the dimer Disulfide bonds: the polypeptide chain has 10 cysteine residues that can form five disulfide bonds The toxin shows high affinity for the nicotinic acetylcholine receptor (nAChRs) in the postsynaptic membrane, mostly the ones containing the α3 with an IC50 smaller than 100 nM. This means blocking nicotinic transmission at very low concentrations. Loop II is most important for binding the nAChRs. The two binding surfaces are both the N-terminal extracellular regions of the receptor subunit. These are the 51-70 and 183-201 residues. The most important is Arg-34 at position 36 for binding the α3 receptors. However, κ-bungarotoxin has low affinity for neuromuscular receptors.
Denbu (田麩), a food made by boiling powdered dried bonito flakes in sake and soy sauce, appears in an ancient 17th-century document called "Kokin Ryouri-shu" ("Collection of Ancient and Modern Cookbooks"). Tsukudani (佃煮), which appears in the 19th century colloquial dictionary "Risogonshuran" (俚言集覧) compiled by Ota Zensai (太田全斎), is made by boiling down small fish, shellfish, seaweed, and other ingredients in soy sauce to a rich flavor. The use of tsukudani is similar to furikake, but it is not usually called furikake in Japan today. The modern furikake was invented by several companies between the 1900s and 1920s for the purpose of tasty nourishment. Regarding modern furikake, the Japan Furikake Association recognized Futaba's "Gohan no Tomo" as the original in 1994, but revoked this recognition in 2022 and is conducting a reexamination. The association's conclusion has not been reached as of 2023. One account of the origin of furikake is that it was developed during the Taishō period (1912–1926) by a pharmacist in Kumamoto prefecture named Suekichi Yoshimaru (吉丸末吉). To address calcium deficiency in the Japanese population, Yoshimaru developed a mixture of ground fish bones with roast sesame seeds, poppy seeds, and seaweed that was made into a powder. This product, which he called Gohan no Tomo (ご飯の友, 'A Friend for Rice'), is generally considered the precursor to contemporary furikake. A food company in Kumamoto later acquired the product and was able to sell it commercially.
Sources: en.wikipedia.org
=== Gaming Control Board === While secretary of revenue, Kennedy was also appointed to the Louisiana Gaming Control Board, which is responsible for regulating legalized gambling. He criticized riverboat casino operators for failing to enforce the 21-year age restriction.
The town was founded in 1515 by Mani Ram, a Zamindar under the Lodhi Dynasty. By the 18th century, his descendent Gangaram Singh governed Manimajra and 84 surrounding villages as a Mughal vassal. Following the decline of Mughal authority, Gangaram's son, Gharib Dass, established the independent Manimajra State. Despite early conflicts with the Raja of Nahan, Gharib Dass expanded his territory, seizing Pinjore and establishing the Manimajra Fort as his capital. Upon his death in 1783, his son Raja Gopal Singh took over, eventually receiving the title of Raja from the British in 1814 for his service in the Gurkha campaign. Gopal Singh is notably responsible for building the Mansa Devi Temple (1811–1815). The dynasty continued through Raja Goverdhan Singh and Raja Gurbaksh Singh, ending with Raja Bhagwan Singh, who died without a male heir in 1866. Consequently, the British annexed the state, and the fort later passed to the Raja of Faridkot through marriage.
Selenium is a chemical element; it has symbol Se and atomic number 34. It has various physical appearances, including a brick-red powder, a vitreous black solid, and a grey metallic-looking form. It seldom occurs in this elemental state or as pure ore compounds in Earth's crust. Selenium (from σελήνη 'moon') was discovered in 1817 by Jöns Jacob Berzelius, who noted the similarity of the new element to the previously discovered tellurium (named for the Earth). Selenium is found in metal sulfide ores, where it substitutes for sulfur. Commercially, selenium is produced as a byproduct in the refining of these ores. Minerals that are pure selenide or selenate compounds are rare. The chief commercial uses for selenium today are glassmaking and pigments. Selenium is a semiconductor and is used in photocells. Applications in electronics, once important, have been mostly replaced with silicon semiconductor devices. Selenium is still used in a few types of DC power surge protectors and one type of fluorescent quantum dot. Although trace amounts of selenium are necessary for cellular function in many animals, including humans, both elemental selenium and (especially) selenium salts are toxic in even small doses, causing selenosis. Symptoms include (in decreasing order of frequency): diarrhea, fatigue, hair loss, joint pain, nail brittleness or discoloration, nausea, headache, tingling, vomiting, and fever.
Sources: en.wikipedia.org
== History == It is generally accepted that dry ice was first observed in 1835 by French inventor Adrien-Jean-Pierre Thilorier (1790–1844), who published the first account of the substance. In his experiments, he noted that when opening the lid of a large cylinder containing liquid carbon dioxide, most of the liquid carbon dioxide quickly evaporated. This left only solid dry ice in the container. In 1924, Thomas B. Slate applied for a US patent to sell dry ice commercially. Subsequently, he became the first to make dry ice successful as an industry. In 1925, this solid form of CO2 was trademarked by the DryIce Corporation of America as "Dry ice", leading to its common name. That same year the DryIce Co. sold the substance commercially for the first time, marketing it for refrigeration purposes.
The Republic of Korea Armed Forces issues two types of field rations, Type I and Type II. Type I ration has ready-to-eat foods packed in foil-plastic trilaminate pouches, placed in turn inside a thin cardboard box. Typical contents include: 1 pouch (250 g) precooked white rice with meat and vegetables, plus a separate seasoning packet; 1 pouch (250 g) precooked rice with red beans; 1 packet (100 g) of 6 pork sausages in BBQ; 1 packet (100 g) kimchi; and 1 packet (50 g) cooked black beans. The Type II ration is a smaller, lighter, freeze-dried single-meal ration consisting of several small pouches packed inside a larger gray plastic pouch measuring 225 mm x 200 mm x 90 mm and weighing 278 g. Typical contents include: freeze dried rice (various flavors, usually with meat and vegetables included), a pouch of instant soup, flavored sesame oil, seasoning and spice packets, dried chives and chocolate.
=== Philosophy === While positive psychologists focus on empirical research of specific factors, philosophers place more emphasis on the general nature, overall function, and conceptual foundations of well-being. They explore its essential features by developing and comparing theories of well-being, such as hedonistic theories, desire theories, and objective list theories. Philosophers also investigate the foundational principles of the scientific study of well-being. Considering that well-being has both subjective and evaluative aspects, they seek to determine whether scientific objectivity is possible and to what extent well-being can be quantified and compared between individuals. Some philosophers challenge the concept of well-being, understood as what is ultimately good for someone. For instance, philosopher G. E. Moore (1873–1958) rejects the idea that something can be good relative to a person, asserting instead that all values are impersonal. Another criticism suggests that the concept of well-being is incoherent, arguing that it groups together diverse elements without a shared essence. Despite these criticisms, well-being plays a central role in ethics and value theory. Welfarism is the view that well-being is the only basic source of value. It holds that everything else, like intelligence and health care, is only valuable to the extent that it promotes well-being and reduces ill-being. Pure welfarists argue that the raw sum of everyone's well-being is all that matters.
== Season 10 (2024) == This season is themed around mad scientists, with host John Henson as the owner of "Henson Laboratories". In each challenge, bakers are asked to create desserts to appease the evil spirits that haunt the lab.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.